Scientist Finds New Weapon Against Ovarian Cancer

Scientist Finds New Weapon Against Ovarian Cancer

IAPO | Exploring the Impact of Public Involvement: Understanding the role of theory, practice & culture – Oxford, UK - 19 March 2009 | A global voice for patients

2009 GOC (Gynecologis Oncologists of Canada) meeting Program

9th Annual CPD Program Learning
Objectives
At the conclusion of this conference, attendees will:
• Understand PARP inhibitors and their potential role in ovarian cancer
treatment
• Review the role of chemotherapy before primary surgery and in
combination for recurrent ovarian cancer
• Learn about new innovations in cervical cancer treatment
• Review optimal thromboprophylaxis prior to gynecologic oncology surgery
• Evaluate recent literature on lymphadenectomy and chemotherapy in early
endometrial cancer

Identification of a Predictive Biomarker for Hematologic Toxicities of Gemcitabine

Patient Involvement in Decisions to Limit Treatment: The Crucial Role of Agreement Between Physician and Patient

"Conclusion Only half of the patients were involved in DLT. Surprisingly, the main predictor of patient involvement was not their medical condition, but agreement with physicians' palliative treatment goals. These results show that if physicians switch to comfort care in terminally ill patients and patients are not yet prepared to follow this line, treatment limitations are often decided without involving the patient."